MedTrace Logo

Trodat 1 SPECT and Dopamine Polymorphism

NCT01381302 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2016-02-09

No results posted yet for this study

Summary

The study population will include 100 parkinsonian patients in early stage of disease, with total duration not exeeding 5 years.

The patients will undergo neurologic examination and evaluation of disease severity using the unified PD rating scale. Subsequently a brain SPECT will be performed using Tc-99m-Trodat1.

Conditions

  • Parkinson Disease

Sponsors & Collaborators

  • Wolfson Medical Center

    lead OTHER_GOV

Principal Investigators

  • Mordechai Lorberboym, MD · Edith Wolfson Medical Center

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01381302 on ClinicalTrials.gov